Oxygen Heterocycle Patents (Class 424/78.38)
-
Patent number: 8106146Abstract: The invention describes poly(ortho ester) polymers that include at least one therapeutic compound in the polymer backbone. The therapeutic compound includes at least one phenol residue and an aliphatic alcohol residue or two or more phenolic residues.Type: GrantFiled: April 23, 2010Date of Patent: January 31, 2012Assignee: Medtronic, Inc.Inventors: Michael E. Benz, Erica M. Tenbroek, Lian Leon
-
Patent number: 8097274Abstract: Provided herein are skin substitutes suitable for use in a living subject for purpose of repairing damaged tissues, methods of producing the skin substitutes and their uses. A biocomposite membrane comprising poly(?-caprolactone) (PCL) and at least one material selected from collagen and gelatin is provided. In one embodiment, the biocomposite is a 2-component membrane of PCL and gelatin. In another embodiment, the biocomposite is a 3-component membrane of PCL, collagen and gelatin. The bio-composite membrane may be used directly in vivo as a wound dressing, or as a support for cell growth on each side of the membrane to produce an in vitro cultivated artificial skin for future in vivo and/or in vitro applications.Type: GrantFiled: October 27, 2006Date of Patent: January 17, 2012Assignee: National Defense Medical CenterInventors: Allan Gerald Arthur Coombes, Eric Frank Adams, Niann-Tzyy Dai, Tsung-Hsun Liu, Ming-Kung Yeh
-
Publication number: 20120003177Abstract: Curcumin, a polyphenol extracted from the rhizome turmeric, has been polymerized to produce a polymer material having a backbone of one or more repeating structural units, at least one of which comprises a curcumin monomer residue. These curcumin-containing polymers have a wide range of pharmacological activities, including, among others antitumor, antioxidant, antiinflammatory, antithrombotic and antibacterial activities. Certain species of these polymers have exhibited remarkable antitumor activity. Water-soluble curcumin derivatives and their use as prodrugs and prodrug carriers are also disclosed.Type: ApplicationFiled: September 17, 2009Publication date: January 5, 2012Inventors: Youqing Shen, Huadong Tang, Edward Van Kirk, William Murdoch, Maciej Radosz
-
Patent number: 8067505Abstract: Methods for preparing water soluble, non-peptidic polymers carrying carboxyl functional groups, particularly carboxylic acid functionalized poly(ethylene glycol) (PEG) polymers are disclosed, as are the products of these methods. In general, an ester reagent R(C?0)OR?, wherein R? is a tertiary group and R comprises a functional group X, is reacted with a water soluble, non-peptidic polymer POLY-Y, where Y is a functional group which reacts with X to form a covalent bond, to form a tertiary ester of the polymer, which is then treated with a strong base in aqueous solution, to form a carboxylate salt of the polymer. Typically, this carboxylate salt is then treated with an inorganic acid in aqueous solution, to convert the carboxylate salt to a carboxylic acid, thereby forming a carboxylic acid functionalized polymer.Type: GrantFiled: February 9, 2011Date of Patent: November 29, 2011Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Antoni Kozlowski, Lihong Guo
-
Publication number: 20110274739Abstract: Resorbable polymer barrier membranes and methods of their applications are disclosed. In a broad embodiment, methods of governing tissue growth, or preventing tissue growth into a certain spatial area, includes the step of forming a spatial barrier with the present resorbable barrier membrane. The barrier membrane separates a tissue-growth area and a non-bone-growth area, and prevents tissue from growing into the non-growth area.Type: ApplicationFiled: May 10, 2010Publication date: November 10, 2011Inventors: Kai Deusch, Christopher J. Calhoun, Kenton R. Mullins
-
Publication number: 20110244001Abstract: A composite material containing polymeric nanofibers, themselves containing NO-donor molecules, imbibed with an elastomer matrix is permeable to both water and gas so that dissociation reactions in the presence of water releases NO gas in a sustained manner. The NO-donor nanofibers may be formed by synthesizing acceptable NO-donor molecules, blending such molecules in solution with PVP, PCL or PVAc, electrospinning the blend at relatively high voltage for form fiber mats, applying PDMS rubber to the fiber mat and crosslinking it. The resulting NO-releasing electrospun fiber composite may be used in medical devices such as catheters, stents, or vascular grafts, with the purpose of releasing nitric oxide within a controlled rate and for a sustained period of time, as well as other known medical applications for NO.Type: ApplicationFiled: April 6, 2011Publication date: October 6, 2011Applicant: Syracuse UniversityInventors: Patrick Mather, Ifeanyi Onyejewke, Kazuki Ishida
-
Patent number: 8003089Abstract: The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.Type: GrantFiled: March 12, 2003Date of Patent: August 23, 2011Assignee: Beijing Jiankai Technology Co., Ltd.Inventors: Shishan Ji, Dequan Zhu
-
Publication number: 20110200676Abstract: A composition comprising a polymer that comprises oxidated hyaluronic acid cross-linked by a dihydrazide is disclosed. The polymer is a hydrogel exhibiting the following properties: a) transparent and colorless; and b) transforming from a liquid state into a gel-matrix at 37° C. These characteristics make it useful as a vitreous humor substitute.Type: ApplicationFiled: August 31, 2010Publication date: August 18, 2011Applicant: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Feng-Huei LIN, Wen-Yu Su, Yu-Chun Chen, Ko-Hua Chen
-
Publication number: 20110189121Abstract: The invention relates to a method for producing tablets comprising a polyallylamine polymer, comprising the steps (i) preparation of a polyallylamine polymer or pharmaceutically compatible salts thereof, optionally in a mixture with one or more pharmaceutical excipients; (ii) compaction to give a slug; (iii) granulation of the slug; and (iv) compression of the resulting granules to give tablets; and also to tablets, sachets and slugs comprising a compacted polyallylamine polymer. In addition, the invention relates to tablets comprising a polyallylamine polymer, in particular Sevelamer, with a bimodal pore size distribution.Type: ApplicationFiled: March 20, 2009Publication date: August 4, 2011Applicant: ratiopharm GmbHInventors: Maria Genth, Max-Werner Scheiwe
-
Publication number: 20110158933Abstract: A pharmaceutical preparation containing polymeric compounds as shown in the specification. This preparation can be used to improve liver function and treat liver disease, and promoting liver tissue regeneration.Type: ApplicationFiled: October 20, 2010Publication date: June 30, 2011Applicant: Industrial Technology research Institute (ITRI)Inventors: Shau-Feng Chang, Chun-Hsien Ma, Kuo-Yi Yang, Chien-Tung Lin, Shyh-Horng Lin, Kai-Wen Huang
-
Publication number: 20110159087Abstract: Disclosed herein are pharmaceutical compositions comprising wet granulated bile acid sequestrants having the general Formula I shown, and their process of preparation. The present invention also discloses process for preparation of Colesevelam hydrochloride, an antilipemic agent.Type: ApplicationFiled: September 2, 2009Publication date: June 30, 2011Inventors: Dhananjay Govind Sathe, Harish Kashinath Mondkar, Mantripragada Narayan Rao, Samadhan Daulat Patil, Tanaji Shamrao Jadhav, Ashok Omray, Varsha Shashank Choudhary, Yogesh Sharad Bhide
-
Patent number: 7964182Abstract: The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion source.Type: GrantFiled: December 1, 2010Date of Patent: June 21, 2011Assignee: USV, LtdInventors: Ashok Omray, Varsha Shashank Choudhary, Yogesh Sharad Bhide
-
Patent number: 7943141Abstract: The present disclosure provides terminally activated monofunctional POZ derivatives having a range of functional active groups allowing conjugation of the monofunctional POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed terminally activated monofunctional POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives.Type: GrantFiled: February 28, 2008Date of Patent: May 17, 2011Assignee: Serina Therapeutics, Inc.Inventors: J. Milton Harris, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese
-
Publication number: 20110081309Abstract: Provided are healthcare compositions comprising a superhydrophilic amphiphilic copolymer, a micellar thickener, and a cosmetically-acceptable or pharmaceutically-acceptable carrier. Also, provided are methods of cleansing or treating a mammal by applying healthcare compositions of the present inventions to the mammalian body.Type: ApplicationFiled: October 7, 2009Publication date: April 7, 2011Inventors: Michael J. Fevola, Frank C. Sun, Joseph J. LiBrizzi, Joseph B. Gardner, Russell M. Walters
-
Patent number: 7919562Abstract: The present invention relates to supramolecular polymers containing sequence-selective hydrogen bonding subunits in their backbone which form double helices. The invention allows for tuning of the numbers and sequences of donor/acceptor units incorporated in any one crosslinking hydrogen bonding subunit and hence tuning of the interaction strength not only through the amount of crosslinking material incorporated but also through modulation of the strength of the crosslinking interactions. It also allows for the incorporation of more than one type of crosslinking agent in the material allowing for multiple strengths of crosslinking which are each tunable with regard to disruption from solvent, temperature and stress. Hydrogen bond strength between oligomeric chains can be tailored through modification of the numbers and sequences of the donors/acceptors in the oligomers.Type: GrantFiled: May 31, 2007Date of Patent: April 5, 2011Assignee: The University of Western OntarioInventors: James Andrew Wisner, Jiaxin Li
-
Publication number: 20110064820Abstract: The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion source.Type: ApplicationFiled: December 1, 2010Publication date: March 17, 2011Inventors: Ashok Omray, Varsha Shashank Choudhary, Yogesh Sharad Bhide
-
Patent number: 7897698Abstract: The present application discloses a method of modifying a macromolecule, the method comprising the steps of (i) providing the macromolecule; (ii) providing a compound of the general formula (I): wherein N is a primary amino group protected with the protecting group P, wherein the protecting group involves both free valences of the primary amino group; m is an integer of 1-12 and n is an integer of 1-2000; R1 and R2 are independently selected from the group consisting of hydrogen and C1-4-alkyl; and X is a reactive group; and (iii) allowing the compound of the general formula (I) to react with the macromolecule so as to form grafts on the macromolecule. Compounds of the general formula (i) and a method for the preparation thereof are also disclosed.Type: GrantFiled: August 25, 2006Date of Patent: March 1, 2011Assignee: Novo Nordisk A/SInventors: Ib Johannsen, Roice Michael
-
Publication number: 20110044935Abstract: The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P188) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e.g., for treating dystrophin-deficient cells (e.g., myocytes)).Type: ApplicationFiled: October 29, 2010Publication date: February 24, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Joseph M. Metzger, Dewayne Townsend, Soichiro Yasuda, Daniel E. Michele
-
Publication number: 20110044934Abstract: The present invention provides for treating textiles with a composition comprising the reaction product of a) an oxirane or oxetane compound comprising at least two oxirane or oxetane groups; and b) an amino silane having the formula: N(H)(R1)R2Si(OR3)3-a-b-c(OR4)a(R5Si(OR6)d(R7)e)bR8c with R1 is chosen from the group consisting of H or a monovalent hydrocarbon radical containing one to 20 carbon atoms; R2 and R5 are independently selected from a group consisting of oxygen or a divalent linear or branched hydrocarbon radical consisting of 1-60 carbons; R4 is a hydrocarbon radical that contains 3 to 200 carbon atoms; R3, R6, R7, and R8 and are each independently selected from the group of monovalent linear or branched hydrocarbon radicals having from 1 to 200 carbon atoms; the subscript b is zero or a positive number and has a value ranging from 0 to 3; the subscripts a, and c are zero or positive and have a value ranging from 0 to 3 subject to the limitation that (a+b+c)?3; the subscripts d and e are zero orType: ApplicationFiled: October 30, 2008Publication date: February 24, 2011Inventor: Benjamin Falk
-
Publication number: 20110038829Abstract: This document relates to methods and materials for administering bile acid sequestrants to treat conditions associated with diarrhea. For example, formulations designed for the delivery of a bile acid sequestrant (e.g., colesevelam) to treat diarrhea are provided.Type: ApplicationFiled: August 5, 2010Publication date: February 17, 2011Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventor: Michael L. Camilleri
-
Publication number: 20110020228Abstract: A method for the treatment of cancer involves delivering a surface active agent to an organism, where the surface active agent selectively partitions to and kills cancer cells as opposed to healthy cells. The surface active agent can be an ionic or a non-ionic surfactant with a HLB of less than 29 or a mixture of surface active agents with a HLB of less than 40, where the hydrophobic portion is a lesser fraction of the surface active agent than the hydrophilic portion. A fluorescence method of detecting and locating cancer cells in an organism involves delivering a surface active agent, where the surface active agent includes a fluorescence moiety that upon selective partitioning of the surface active agent to the cancer cells and irradiation by a radiation source to excite the fluorescence moiety, a fluorescence emission is observed permitting the detection and location of the cancerous tissue by local volumes of relatively high intensity emission.Type: ApplicationFiled: February 2, 2009Publication date: January 27, 2011Applicant: University of Florida Resarch Foundation, Inc.Inventors: Brij M. Moudgil, Manoj Varshney, Stephen R. Grobmyer
-
Publication number: 20110002979Abstract: The invention provides a styrene maleic anhydride based synergistic formulation comprising styrene maleic anhydride [SMA] having lower molecular weight and styrene maleic anhydride [SMA] having higher molecular weight dissolved in DMSO, and being capable of preventing the prostate cancer as well as causing male contraception even when administered in smaller doses for one or two administrations in the life time and predominantly causing no or minimal side effects, and still being reasonably affordable by common man, and the formulation being capable of traveling along the vas deferens after causing male contraception in the vas deferens to the prostate gland and getting absorbed into the epithelial zone of the prostate gland.Type: ApplicationFiled: March 9, 2009Publication date: January 6, 2011Inventor: Sujoy Kumar Guha
-
Publication number: 20100310607Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.Type: ApplicationFiled: March 19, 2010Publication date: December 9, 2010Applicant: Abbott LaboratoriesInventors: Tzuchi R. Ju, Claudia M. Davila, Yi Gao, Linda E. Gustavson, David LeBlond, Tong Zhu
-
Patent number: 7846426Abstract: The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188—P188) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e.g., for treating dystrophin-deficient cells (e.g., myocytes)).Type: GrantFiled: February 27, 2006Date of Patent: December 7, 2010Assignee: The Regents of the University of MichiganInventors: Joseph M. Metzger, Dewayne Townsend, Soichiro Yasuda, Daniel E. Michele
-
Patent number: 7838122Abstract: Compounds exhibiting angiogenic properties incorporating the structure of Formula I: R3—NH—NH—C(?O)—R2—P—R1??(I) wherein P is a water-soluble, biodegradable polymer, R1 is hydrogen, lower alkyl, lower alkoxy or —R2—C(?O)—NH—NH—R3; each R2 is independently —CH2—, —NH— or O; and each R3 is independently hydrogen or a residue of a naturally occurring alpha-L-amino acid or dipeptide thereof. Polymer networks crosslinked with hydrazide compounds are also disclosed, together with implantable medical devices incorporating the compounds and crosslinked polymers, and angiogenesis-promoting treatment methods, including wound-treatment methods.Type: GrantFiled: May 6, 2008Date of Patent: November 23, 2010Assignee: Rutgers, the State University of New JerseyInventors: Joachim B. Kohn, Kristen S. Labazzo, Durgadas Bolikal
-
Publication number: 20100285144Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer or neurological deficits. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: March 29, 2010Publication date: November 11, 2010Inventors: Scott Eliasof, Thomas C. Crawford, Geeti Gangal, Lawrence Alan Reiter, Pei-Sze Ng
-
Patent number: 7820734Abstract: The present disclosure provides lubricious antimicrobial coating vehicles for medical devices capable of reducing the coefficient of friction of such devices upon exposure thereof to moisture and imparting antimicrobial properties to said devices. The coating vehicle allows the introduction of a pharmacological additive having a release rate that is within acceptable pharmacokinetic criteria.Type: GrantFiled: October 31, 2007Date of Patent: October 26, 2010Assignee: Tyco Healthcare Group LPInventor: Diane L. McGhee
-
Publication number: 20100266653Abstract: This invention relates to a biocidal composition comprising fine particles comprising polyacrolein wherein at least 90% of particles are of a size no more than 30 microns. Preferably at least 90% of particles are of size no more than 5 microns and still more preferably at least 90% of particles are of size no more than 1 micron.Type: ApplicationFiled: July 18, 2008Publication date: October 21, 2010Applicant: CHEMEQ LTDInventors: Robert William Dunlop, Gautam Dalwadi
-
Publication number: 20100266523Abstract: The invention relates to compositions of polyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers of units of the formula (I), wherein said units are characterised by the simultaneous presence of a phloroglucinol-type core (core A) and of a catechol-type core (core B) bonded together by a segment of 3 carbons such as C, said derivatives being over-activated in terms of nucleophilic power by the alkylation of at least one phenol function of each constituent monomer unit, and stabilised by the esterification of all the others with mixtures of fatty acids in proportions representing those of vegetable oils mainly consisting of AGI. These compositions can particularly be used in cosmetics, nutrition and therapy.Type: ApplicationFiled: November 17, 2008Publication date: October 21, 2010Inventor: Joseph Vercauteren
-
Publication number: 20100260703Abstract: Methods for soft tissue repair and/or augmentation using injectable, biodegradable polymers are described herein. In one embodiment, the polymer compositions are liquid or pastes at room temperature. In a preferred embodiment, the polymer composition contains liquid or pasty hydroxy fatty acid-based copolyesters, polyester-anhydrides, or combinations thereof. The viscosity of the polymers increases upon contact with bodily fluid to form a solid or semisolid implant suitable for soft tissue repair and/or augmentation. In another embodiment, the polymer composition contains particles of a polymer stereocomplex. One or more active agents may be incorporated into the polymer compositions. Suitable classes of active agents include local anesthetics, anti-inflammatory agents, antibiotics, analgesics, growth factors and agents that induce and/or enhance growth of tissue within the filled cavity or control the growth of a certain type of tissue, and combinations thereof.Type: ApplicationFiled: October 5, 2008Publication date: October 14, 2010Inventors: Lior Yankelson, Abraham J. Domb
-
Publication number: 20100254935Abstract: Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH2CH2— group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.Type: ApplicationFiled: February 19, 2010Publication date: October 7, 2010Applicant: Genzyme CorporationInventors: Chad C. Huval, Stephen Randall Holmes-Farley, Pradeep K. Dhal
-
Publication number: 20100166861Abstract: The present disclosure provides a pharmaceutical composition for the treatment of hyperphosphatemia in mammals. The composition includes sevelamer and copovidone. The composition is provided in the form of a coated tablet having a compressed core. Also disclosed are methods for the manufacture of such tablets, and methods for treating hyperphosphatemia in mammalian patients using the disclosed compositions.Type: ApplicationFiled: December 29, 2008Publication date: July 1, 2010Inventor: Kelly Noel Lynch
-
Publication number: 20100158855Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: ApplicationFiled: December 28, 2009Publication date: June 24, 2010Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Publication number: 20100143287Abstract: The present invention relates to new trifluoromethylphenyl modulators of calcium-sensing receptor, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 8, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Patent number: 7714114Abstract: Conjugates of an EPO moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making conjugates, and methods of administering compositions comprising such conjugates to a patient.Type: GrantFiled: February 16, 2006Date of Patent: May 11, 2010Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Gayle Stephenson
-
Publication number: 20100098766Abstract: Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances.Type: ApplicationFiled: March 7, 2008Publication date: April 22, 2010Applicant: MERZ PHARMA Gmbh & CO. KGaAInventors: Edgar Mentrup, Rainer Pooth, Thomas Wimmer, Sigrid Drewes
-
Patent number: 7674452Abstract: Polymers and methods of making them are described. The polymers may be used to coat living cells. The polymer-coated cells are useful in cell therapy applications.Type: GrantFiled: February 22, 2006Date of Patent: March 9, 2010Assignee: Nitto Denko CorporationInventors: Sang Van, Yasunobu Tanaka, Lei Yu
-
Publication number: 20100008887Abstract: It is intended to provide a composition having an excellent anti-obesity action without potential for adverse side effects and the like even if taken for a long period of time. The composition is an anti-obesity composition containing an acacia bark derivative.Type: ApplicationFiled: August 10, 2006Publication date: January 14, 2010Inventors: Yusho Nakamoto, Keiko Ono
-
Publication number: 20100008988Abstract: The present invention provides pharmaceutical compositions, essentially comprising less than about 95% by weight of an aliphatic amine polymer. The present invention relates to pharmaceutical compositions comprising aliphatic amine polymers of sevelamer hydrochloride, sevelamer carbonate and colesevelam hydrochloride; and methods of preparing pharmaceutical compositions thereof.Type: ApplicationFiled: July 13, 2009Publication date: January 14, 2010Applicant: GLENMARK GENERICS, LTD.Inventors: KAMAL MEHTA, SRINIVAS GANGA ARRA, HIDAYTULLA AGA
-
Publication number: 20090324537Abstract: The present invention relates to swellable polymeric materials comprising a synthetic polymer, or copolymer, comprising a carboxylic group and a biopolymer that are suitable for bioapplications. Because of their ability to swell, the polymeric materials are suitable for use as stomach fillers for the treatment of being over weight or obese, or for inducing the feeling of being satiated. Methods for preparing the swellable polymeric materials comprising aqueous reaction systems are also disclosed.Type: ApplicationFiled: March 26, 2009Publication date: December 31, 2009Inventors: Mircea Dan Bucevschi, Monica Colt, Mendy Axlerad
-
Publication number: 20090280178Abstract: Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation.Type: ApplicationFiled: August 31, 2007Publication date: November 12, 2009Inventors: Deepak Anant Hedge, Varsha Shashank Choudhary, Venkatasubramanian Radhakrjshnan Tarur, Dhananjay Govind Sathe, Harish Kashinath Mondkar, Samadhan Daulat Patil, Sasikumar Mohan Thoovara, Yogesh Sharad Bhide
-
Publication number: 20090252702Abstract: The present invention relates to the use of amphiphilic block copolymers for treating and preventing cancer, and in particular by reducing the proliferation rate of cancer cells. Preferred block copolymers comprises a central hydrophobic chain, preferably a polypropylene oxide chain, two which at least two hydrophilic side chains, preferably polyethylene oxide chains, are connected.Type: ApplicationFiled: April 23, 2007Publication date: October 8, 2009Applicant: BRUCE MEDICAL ABInventors: Lars Bruce, Ingrid Bruce
-
Patent number: 7588754Abstract: Condensation polymerization methods are used to prepare various biodegradable polyacetals of the general formula (I). Such polymers are useful for variety of drug, biomolecule and imaging agent delivery applications.Type: GrantFiled: May 10, 2005Date of Patent: September 15, 2009Assignee: Nitto Denko CorporationInventors: Sang Van, Hyun Sik Chae, Lei Yu
-
Publication number: 20090208444Abstract: A sanitising formulation comprising a solution of an acidic polymer and an anionic surfactant in a liquid vehicle. Suitable acidic polymers are those which include adjacent —[—CR1.COOH—]— units where R1 is defined in their structure, for example polymers based on maleic acid moieties which typically include —[—CH.COOH—CH.COOH—]— units, such as known Gantrez™ polymers. A suitable anionic surfact is sodium lauryl sulphate.Type: ApplicationFiled: January 14, 2009Publication date: August 20, 2009Inventors: Simon King, Madhu Parmar, Kimberly Biedermann, Philip Oths
-
Publication number: 20090202467Abstract: This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof. Other embodiments consist of the combination of an amphiphilic block copolymer with a co-solvent, also allowing the injected combination to form a gel within the vein. In other embodiments, an amphiphilic block copolymer is combined with a co-solvent, a sclerosant, a vasoconstrictor, water, or combinations thereof. Other embodiments of the invention include a combination of a sclerosant such as sodium tetradecyl sulfate or polidocanol with a vasoconstrictor, preferably a long-acting vasoconstrictor such as oxymetazoline. Other embodiments are directed to compositions and methods of treating venous and arteriovenous malformations and cancer.Type: ApplicationFiled: December 15, 2008Publication date: August 13, 2009Inventor: Richard W. Bock
-
Patent number: 7563460Abstract: A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.Type: GrantFiled: February 25, 2005Date of Patent: July 21, 2009Assignee: Med Five, Inc.Inventors: Alec D. Keith, William E. Crisp
-
Publication number: 20090175933Abstract: A preparation for the treatment of diarrhoea comprising a bulking agent and an anti-diarrhoeal agent wherein the anti-diarrhoeal agent is provided in the form of an anti-motility agent.Type: ApplicationFiled: October 6, 2006Publication date: July 9, 2009Applicant: COLOCAPS PTY LTDInventor: Michael David Levitt
-
Publication number: 20090162314Abstract: A pharmaceutical composition comprising an aliphatic amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable magnesium compound comprising a magnesium ion is disclosed. A method of treating hyperphosphatemia in a patient is also disclosed. The method comprises the step of administering to the subject an effective amount of the disclosed pharmaceutical composition.Type: ApplicationFiled: November 7, 2006Publication date: June 25, 2009Inventors: Chad C. Huval, Pradeep K. Dhal, Stephen Randall Holmes-Farley
-
Publication number: 20090148397Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.Type: ApplicationFiled: July 17, 2008Publication date: June 11, 2009Inventors: Edward James Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan, David F. Sesin
-
Publication number: 20090130182Abstract: Topical compositions having as the active ingredient a hydrophilic material, such as a polyalkylene oxide homopolymer or copolymer, and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of a cream, gel, lotion, spray, foam, paste, patch, suspension or dispersion. In the preferred embodiment, the formulation is a gel. The composition may contain a penetration enhancer, most preferably one with membrane disruptive properties. In one embodiment, the compositions are incorporated onto or into disposables such as hemorrhoid wipes, gauze, sponge, bandages, and wraps; mouth guards, dental trays; needles or catheters; adult diapers; gloves, socks or wrist bands, for ease of application. The composition is applied topically to a site at or adjacent to a painful region. The composition is reapplied as necessary.Type: ApplicationFiled: June 13, 2008Publication date: May 21, 2009Inventors: Bryan Todd Oronsky, Neil Charles Oronsky, Arnold L. Oronsky